EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis

Chuan Qin, Ming-Hao Dong, Luo-Qi Zhou, Yun-Hui Chu, Xiao-Wei Pang, Jia-Yi He, Ke Shang, Jun Xiao, Li Zhu, Huan Ye, Song-Bai Cai, Di Wang und 5 weitere

Cell · 2025-11 · 188 (23) · 6414-6423.e11

DOI: 10.1016/j.cell.2025.09.020 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell, 2025-11. Verfasst von Chuan Qin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Dise…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, B-Cell Maturation Antigen, Receptors, Chimeric Antigen, Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveB-Cell Maturation AntigenReceptors, Chimeric AntigenMultiple Sclerosis, Chronic ProgressiveMultiple SclerosisHumansFemaleMaleMiddle AgedAdultPlasma CellsB-LymphocytesT-Lymphocytes

Stichwörter der Autor:innen

B cell maturation antigenCARchimeric antigen receptor T cellprogressive multiple sclerosissingle-cell RNA sequencing

Substanzen

B-Cell Maturation AntigenReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurology, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei 4300…
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hub…
  • Nanjing IASO Biotherapeutics Ltd., Jiangsu, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qin, C., Dong, M. H., Zhou, L. Q., Chu, Y. H., Pang, X. W., He, J. Y., Shang, K., Xiao, J., Zhu, L., Ye, H., Cai, S. B., Wang, D., Bu, B. T., Meyer Zu Hörste, G., Li, C. R., Tian, D. S., & Wang, W. (2025). Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell, 188(23), 6414-6423.e11. https://doi.org/10.1016/j.cell.2025.09.020

Vancouver

Qin C, Dong MH, Zhou LQ, Chu YH, Pang XW, He JY, et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell. 2025;188(23):6414-6423.e11. doi:10.1016/j.cell.2025.09.020

BibTeX
@article{Qin2025,
  author = {Qin, Chuan and Dong, Ming-Hao and Zhou, Luo-Qi and Chu, Yun-Hui and Pang, Xiao-Wei and He, Jia-Yi and Shang, Ke and Xiao, Jun and Zhu, Li and Ye, Huan and Cai, Song-Bai and Wang, Di and Bu, Bi-Tao and Meyer Zu Hörste, Gerd and Li, Chun-Rui and Tian, Dai-Shi and Wang, Wei},
  title = {Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {23},
  pages = {6414--6423.e11},
  doi = {10.1016/j.cell.2025.09.020}
}
Kostenlos starten →